Comparing immunotherapy to radiation after successful treatment for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced head and neck squamous cell carcinoma that has been surgically removed after chemotherapy and immunotherapy, and there was no cancer left in the removed tissue.
- You are between 18 and 65 years old.
- Your blood counts, liver and kidney function, thyroid, and heart tests are within a certain range.
- You have not had other cancers, active autoimmune diseases, or serious infections like HIV or untreated hepatitis B or C.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study and for several months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced head and neck cancer who had good response to chemotherapy plus immunotherapy before surgery. It compares two different follow-up treatments: more immunotherapy or radiation therapy to help prevent cancer from coming back.
This trial tests whether 2 or 4 cycles of pembrolizumab (immunotherapy) plus carboplatin and nab-paclitaxel (chemotherapy) before surgery works better for people with advanced head and neck cancer that can be removed. The goal is to see if fewer treatments are just as effective.
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
This trial looks at whether patients with head and neck squamous cell carcinoma who had a good response to chemotherapy and immunotherapy before surgery can safely have less radiation after surgery. It aims to reduce side effects while keeping treatment effective.
This trial compares two approaches after initial treatment: radiation therapy versus an immunotherapy drug (PD-1 inhibitor) to see which better prevents cancer from coming back. It is for people with advanced oral or throat cancer who have already completed chemoimmunotherapy and surgery to remove all visible cancer.
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.